ArticleScientific reports2025
Genetically engineered BMSCs promote dopamine secretion and ameliorate motor dysfunction in a Parkinson's disease rat model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cryopreservable dopaminergic progenitors derived from human iPSCs with accelerated loss of pluripotency and early functional restoration in Parkinsonian rats.NPJ Parkinson's disease · 2026Article
- Mesenchymal Stem Cells and Extracellular Vesicles for Neurodegenerative Diseases: Therapeutic Advances and Challenges.International journal of nanomedicine · 2026Review
- Combined bone marrow mesenchymal stem cell-derived nanovesicles and low-level laser therapy potentiate proliferation and osteogenesis of bone marrow mesenchymal stem cells.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Regenerative therapy based on mesenchymal stem cells (MSCs) is regarded as a promising strategy for treating Parkinson's disease (PD). Previous studies have shown that mesenchymal stem cell transplantation has the potential to treat Parkinson's disease, but its specific mechanism of action is still unclear. In the present study, we generate genetically engineered bone marrow mesenchymal stem cells (BMSCs) encoding three critical genes (TH, DDC, and GCH1) for dopamine synthesis (DA-BMSCs). The DA-BMSCs maintain their MSCs characteristics and stable ability to secrete dopamine after passage. Moreover, the DA-BMSCs survived and functioned in a rat model of PD treated with 6-OHDA 8 weeks after transplantation. Histological studies showed that DA-BMSCs could differentiate into various functional neurons and astrocytes, and DA-BMSCs derived mature dopaminergic neurons extended dense neurites into the host striatum. Importantly, DA-BMSCs promoted the reconstruction of midbrain dopamine pathways by upregulating striatal dopamine and 5-HT levels and downregulating the levels of inflammatory factors including IL-6, TNF-α, and IL-10. These findings suggest that engineered mesenchymal stem cell transplantation for dopamine synthesis may be an attractive donor material for treating Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.